A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Hematological Malignancies

Trial Profile

A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Hematological Malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 04 May 2016

At a glance

  • Drugs CB 839 (Primary)
  • Indications Diffuse large B cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions
  • Sponsors Calithera Biosciences
  • Most Recent Events

    • 29 Apr 2016 Status changed from recruiting to completed.
    • 27 Jan 2016 Number of treatment arms changed from 1 to 3 as reported by ClinicalTrials.gov record.
    • 27 Jan 2016 Planned number of patients changed from 65 to 25 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top